Trials / Completed
CompletedNCT02867098
XmAb5871 Bioavailability Study
Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Xencor, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
An open label comparison of concentration of the study medication administered intravenously (IV) versus subcutaneously (SC) in healthy volunteers.
Detailed description
The study will enroll approximately 50 eligible healthy male and female subjects between the ages of 18 to 55 inclusive. There will be 5 parallel dose cohorts (Cohorts 1-5) consisting of 10 subjects in each cohort. No subject will be a member of more than 1 cohort. Subjects will receive 3 administrations of study medication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XmAb5871 |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2016-10-21
- Completion
- 2016-10-21
- First posted
- 2016-08-15
- Last updated
- 2017-12-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02867098. Inclusion in this directory is not an endorsement.